HIV-1 infection remains a major public health problem, with an estimated 38.4 million people living with HIV and 1.5 million new HIV infections reported worldwide in 2021. The risk of HIV infection ...

BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving ...

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...

Oral HIV pre-exposure prophylaxis (PrEP) is highly effective for preventing HIV. Several different developments in the US either threaten to increase or promise to decrease PrEP out-of-pocket costs ...

Lenacapavir, a twice-yearly injectable, offers a new HIV prevention method, improving adherence compared to more frequent regimens. Phase 3 trials showed lenacapavir's high efficacy in preventing HIV, ...

Elizabeth M. Stone ([email protected]), Rutgers University, New Brunswick, New Jersey. Nicholas J. Seewald, University of Pennsylvania, Philadelphia, Pennsylvania ...

Nigerians are scrambling for Lenacapavir, a new anti-HIV injection for prevention. Learn about this twice-yearly PrEP drug ...